Metformin inhibits HaCaT cell viability via the miR-21/PTEN/Akt signaling pathway

Deng,Yue; Ma,Weiyuan

doi:10.3892/mmr.2017.8364

Metformin inhibits HaCaT cell viability via the miR-21/PTEN/Akt signaling pathway

Authors:
- Yue Deng
- Weiyuan Ma
View Affiliations

Affiliations: Hypertension Center of Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100006, P.R. China, Department of Dermatology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: December 27, 2017 https://doi.org/10.3892/mmr.2017.8364
Pages: 4062-4066

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Substantial preclinical evidence has indicated out a direct anti‑proliferation effect of metformin on various solid tumors; however, further and more detailed exploration into its molecular mechanism remains to be performed. The present study aimed to investigate the effect of metformin on cell viability and its underlying mechanism, in the cultured human skin keratinocyte cell line, HaCaT. In addition, it aimed to clarify the role of the microRNA-21(miR-21)/phosphatase and tensin homolog (PTEN)/AKT serine/threonine kinase 1 (Akt) signaling pathway, which has been hypothesized to be involved in the molecular mechanism of this drug. Cell Counting Kit‑8 assays were used to assess the impact of metformin on cell viability; reverse transcription‑quantitative polymerase chain reaction was used to quantify the expression of miR‑21; western blotting was used to monitor the expression level of PTEN and Akt proteins. In addition, miR‑21 expression levels were artificially manipulated in HaCaT cells using a miR‑21 inhibitor in order to observe the subsequent expression changes of miR‑21 targets and alterations in cell viability. The results indicated that metformin suppressed HaCaT cell growth in a dose‑ and time‑dependent manner (P<0.05). Metformin treatment downregulated miR‑21 expression (t=‑8.903, P<0.05). Following transfection with the miR‑21 inhibitor, HaCaT cell growth was significantly slower than in the control groups (P<0.05). In addition, reduced miR‑21 levels results in significantly increased PTEN protein expression levels and reduced Akt protein expression levels compared with control (P<0.05). Metformin was, therefore, concluded to inhibit HaCaT cell growth in a time‑and dose‑dependent manner, and the miR‑21/PTEN/Akt signaling pathway may serve a crucial role in the molecular mechanism of metformin's effect on HaCaT cells. Therefore the present study presents an advanced insight into the potential inhibitory effect of metformin on tumor cells.

View Figures

View References

1	Wilson VG: Growth and differentiation of HaCaT Ketatinocytes. Methods Mol Biol. 1195:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
2	Coperchini F, Leporati P, Rotondi M and Chiovato L: Expanding the therapeutic spectrum of metformin: From diabetes to cancer. J Endocrinol Invest. 38:1047–1055. 2015. View Article : Google Scholar : PubMed/NCBI
3	Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, Vakhrushev SY, Olsen JV, Hansen L, Bennett EP, et al: Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci USA. 111:pp. E4066–E4075. 2014; View Article : Google Scholar : PubMed/NCBI
4	Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M and Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 122:253–270. 2012. View Article : Google Scholar : PubMed/NCBI
5	Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, Maggiolini M and Belfiore A: Metformin inhibits androgen-induced IGF-IR upregulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology. 155:1207–1221. 2014. View Article : Google Scholar : PubMed/NCBI
6	Fasih A, Elbaz HA, Hüttemann M, Konski AA and Zielske SP: Radiosensitization of Pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res. 182:50–59. 2014. View Article : Google Scholar : PubMed/NCBI
7	Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, Munkarah AR and Rattan R: Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget. 5:4746–4764. 2014. View Article : Google Scholar : PubMed/NCBI
8	Han G, Gong H, Wang Y, Guo S and Liu K: AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther. 16:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A and Szabo E: Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 7:867–885. 2014. View Article : Google Scholar : PubMed/NCBI
10	Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M and Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 122:253–270. 2012. View Article : Google Scholar : PubMed/NCBI
11	Momtazi AA, Derosa G, Maffioli P, Banach M and Sahebkar A: Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther. 20:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
12	Cao DD, Li L and Chan WY: MicroRNAs: Key regulators in the central nervous system and their implication in neurological diseases. Int J Mol Sci. 17:E8422016. View Article : Google Scholar : PubMed/NCBI
13	Cao Y, Xu R, Xu X, Zhou Y, Cui L and He X: Down-regulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 14:1019–1025. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wu YR, Qi HJ, Deng DF, Luo YY and Yang SL: MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer. Tumour Biol. 37:12061–12070. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yang W, Yang Y, Xia L, Yang Y, Wang F, Song M, Chen X, Liu J, Song Y, Zhao Y and Yang C: MiR-221 promotes capan-2 pancreatic ductal adenocarcinoma cells proliferation by targeting PTEN-Akt. Cell Physiol Biochem. 38:2366–2374. 2016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Yang YB, Zhang XH, Yu XL, Wang ZB and Cheng XC: MicroRNA-21 gene and cancer. Med Oncol. 30:3762013. View Article : Google Scholar : PubMed/NCBI
18	Jian H, Wang J, Wang T, Wei L, Li J and Liu L: Identification of rapeseed MicroRNAs involved in early stage seed germination under salt and drought stresses. Front Plant Sci. 7:6582016. View Article : Google Scholar : PubMed/NCBI
19	Guedes JR, Santana I, Cunha C, Duro D, Almeida MR, Cardoso AM, de Lima MC and Cardoso AL: MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease. Alzheimers Dement (Amst). 12:7–17. 2015.
20	Sun H, Wang P, Zhang Q, He X, Zai G, Wang X, Ma M and Sun X1: MicroRNA21 expression is associated with the clinical features of patients with gastric carcinoma and affects the proliferation, invasion and migration of gastric cancer cells by regulating Noxa. Mol Med Rep. 13:2701–2707. 2016. View Article : Google Scholar : PubMed/NCBI
21	Cao J, Liu J, Xu R, Zhu X, Liu L and Zhao X: MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. Mol Med Rep. 13:75–82. 2016. View Article : Google Scholar : PubMed/NCBI
22	Liu RH, Ning B, Ma XE, Gong WM and Jia TH: Regulatory roles of microRNA-21 in fibrosis through interaction with diverse pathways (Review). Mol Med Rep. 13:2359–2366. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yang F, Wang Y, Xue J, Ma Q, Zhang J, Chen YF, Shang ZZ, Li QQ, Zhang SL and Zhao L: Effect of Corilagin on the miR-21/smad7/ERK signaling pathway in a schistosomiasis-induced hepatic fibrosis mouse model. Parasitol Int. 65:308–315. 2016. View Article : Google Scholar : PubMed/NCBI
24	Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, da Silva A, Cao Y, Song M, Nowak J, et al: MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res. 22:3841–3848. 2016. View Article : Google Scholar : PubMed/NCBI
25	Lee JT, Shan J, Zhong J, Li M, Zhou B, Zhou A, Parsons R and Gu W: RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Res. 23:552–564. 2013. View Article : Google Scholar : PubMed/NCBI
26	Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J and Rozengurt E: Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One. 8:e572892013. View Article : Google Scholar : PubMed/NCBI